$VRTX
VERTEX PHARMACEUTICALS INC / MA

2023 Q2 Form 10-Q Financial Statement

#000087532023000012 Filed on May 02, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1
Revenue $2.493B $2.375B
YoY Change 13.52% 13.22%
Cost Of Revenue $308.6M $266.9M
YoY Change 17.88% 8.58%
Gross Profit $2.185B $2.108B
YoY Change 12.93% 13.84%
Gross Profit Margin 87.62% 88.76%
Selling, General & Admin $262.6M $241.1M
YoY Change 21.97% 12.04%
% of Gross Profit 12.02% 11.44%
Research & Development $896.2M $742.6M
YoY Change 49.34% 23.13%
% of Gross Profit 41.02% 35.23%
Depreciation & Amortization $41.40M $38.80M
YoY Change 10.99% 8.08%
% of Gross Profit 1.9% 1.84%
Operating Expenses $1.158B $983.7M
YoY Change 42.04% 20.21%
Operating Profit $1.026B $779.0M
YoY Change -7.22% -25.16%
Interest Expense $142.7M $111.2M
YoY Change -262.16% -225.08%
% of Operating Profit 13.9% 14.27%
Other Income/Expense, Net -$7.600M $1.300M
YoY Change -90.27% -101.79%
Pretax Income $1.162B $891.5M
YoY Change 13.38% -6.63%
Income Tax $245.8M $191.7M
% Of Pretax Income 21.16% 21.5%
Net Earnings $915.7M $699.8M
YoY Change 12.98% -8.17%
Net Earnings / Revenue 36.73% 29.47%
Basic Earnings Per Share $3.55 $2.72
Diluted Earnings Per Share $3.52 $2.69
COMMON SHARES
Basic Shares Outstanding 257.6M shares 257.1M shares
Diluted Shares Outstanding 260.4M shares 260.3M shares

Balance Sheet

Concept 2023 Q2 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $11.24B $10.41B
YoY Change 21.43% 26.41%
Cash & Equivalents $10.15B $9.290B
Short-Term Investments $1.085B $1.124B
Other Short-Term Assets $476.9M $468.7M
YoY Change -13.21% -4.64%
Inventory $603.5M $535.1M
Prepaid Expenses
Receivables $1.556B $1.548B
Other Receivables $0.00 $0.00
Total Short-Term Assets $13.87B $12.97B
YoY Change 20.6% 25.14%
LONG-TERM ASSETS
Property, Plant & Equipment $1.447B $1.448B
YoY Change 2.0% 0.81%
Goodwill $1.088B $1.088B
YoY Change 8.56% 8.56%
Intangibles $603.6M $603.6M
YoY Change 55.97% 50.9%
Long-Term Investments $1.456B $1.180B
YoY Change 1419.73% 1275.41%
Other Assets $1.882B $427.5M
YoY Change 1378.48% 286.18%
Total Long-Term Assets $6.476B $6.009B
YoY Change 58.78% 54.27%
TOTAL ASSETS
Total Short-Term Assets $13.87B $12.97B
Total Long-Term Assets $6.476B $6.009B
Total Assets $20.35B $18.97B
YoY Change 30.59% 33.1%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $363.0M $323.2M
YoY Change 83.33% 86.18%
Accrued Expenses $2.598B $2.326B
YoY Change 22.58% 35.19%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.352B $3.026B
YoY Change 31.14% 38.8%
LONG-TERM LIABILITIES
Long-Term Debt $404.1M $417.6M
YoY Change -16.21% -15.72%
Other Long-Term Liabilities $1.123B $726.5M
YoY Change 872.96% 518.82%
Total Long-Term Liabilities $1.527B $726.5M
YoY Change 1223.14% 518.82%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.352B $3.026B
Total Long-Term Liabilities $1.527B $726.5M
Total Liabilities $4.879B $4.542B
YoY Change 33.72% 35.62%
SHAREHOLDERS EQUITY
Retained Earnings $8.138B $7.223B
YoY Change 70.49% 82.26%
Common Stock $7.372B $7.223B
YoY Change 3.79% 4.18%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $15.47B $14.43B
YoY Change
Total Liabilities & Shareholders Equity $20.35B $18.97B
YoY Change 30.59% 33.1%

Cashflow Statement

Concept 2023 Q2 2023 Q1
OPERATING ACTIVITIES
Net Income $915.7M $699.8M
YoY Change 12.98% -8.17%
Depreciation, Depletion And Amortization $41.40M $38.80M
YoY Change 10.99% 8.08%
Cash From Operating Activities $1.134B $899.9M
YoY Change -0.47% -5.89%
INVESTING ACTIVITIES
Capital Expenditures $59.60M $42.10M
YoY Change -211.82% -33.81%
Acquisitions
YoY Change
Other Investing Activities -$244.3M -$1.792B
YoY Change 2879.27% -14318.25%
Cash From Investing Activities -$303.9M -$1.834B
YoY Change 394.15% 3495.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 17.30M -$294.7M
YoY Change -63.73% 208.91%
NET CHANGE
Cash From Operating Activities 1.134B $899.9M
Cash From Investing Activities -303.9M -$1.834B
Cash From Financing Activities 17.30M -$294.7M
Net Change In Cash 847.8M -$1.216B
YoY Change -24.71% -251.31%
FREE CASH FLOW
Cash From Operating Activities $1.134B $899.9M
Capital Expenditures $59.60M $42.10M
Free Cash Flow $1.075B $857.8M
YoY Change -9.92% -3.9%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
VERTEX PHARMACEUTICALS INC / MA
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000875320
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
000-19319
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
MA
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
50 Northern Avenue
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
04-3039129
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02210
CY2023Q1 dei City Area Code
CityAreaCode
617
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
341-6100
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.01 Par Value Per Share
CY2023Q1 dei Trading Symbol
TradingSymbol
VRTX
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
257551600 shares
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2374800000 usd
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2097500000 usd
CY2023Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
266900000 usd
CY2022Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
245800000 usd
CY2023Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
742600000 usd
CY2022Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
601100000 usd
CY2023Q1 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
347100000 usd
CY2022Q1 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
2000000.0 usd
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
241100000 usd
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
215200000 usd
CY2023Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-1900000 usd
CY2022Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-7500000 usd
CY2023Q1 us-gaap Costs And Expenses
CostsAndExpenses
1595800000 usd
CY2022Q1 us-gaap Costs And Expenses
CostsAndExpenses
1056600000 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
779000000.0 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
1040900000 usd
CY2023Q1 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
122600000 usd
CY2022Q1 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
1600000 usd
CY2023Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-11400000 usd
CY2022Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-14900000 usd
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1300000 usd
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-72800000 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
891500000 usd
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
954800000 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
191700000 usd
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
192700000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
699800000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
762100000 usd
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.72
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.99
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.69
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.96
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
257400000 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
255100000 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
260300000 shares
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
257900000 shares
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
699800000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
762100000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
-800000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
0 usd
CY2023Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
2900000 usd
CY2022Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-2300000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Tax Parent
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent
7400000 usd
CY2022Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
112200000 usd
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
427500000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Tax Parent
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent
-2200000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax Parent
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
-26800000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax Parent
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
10100000 usd
CY2023Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
10000000.0 usd
CY2022Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-12400000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-13900000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-4600000 usd
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
685900000 usd
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
757500000 usd
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9289900000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10504000000 usd
CY2023Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
1124200000 usd
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
274500000 usd
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1547800000 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1442200000 usd
CY2023Q1 us-gaap Inventory Net
InventoryNet
535100000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
460600000 usd
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
468700000 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
553500000 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
12965700000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
13234800000 usd
CY2023Q1 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
1111700000 usd
CY2022Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
1108400000 usd
CY2023Q1 us-gaap Goodwill
Goodwill
1088000000 usd
CY2022Q4 us-gaap Goodwill
Goodwill
1088000000 usd
CY2023Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
603600000 usd
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
603600000 usd
CY2023Q1 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
1359900000 usd
CY2022Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
1246900000 usd
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
336300000 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
347400000 usd
CY2023Q1 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
1081500000 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
409600000 usd
CY2023Q1 us-gaap Assets
Assets
18974200000 usd
CY2022Q4 us-gaap Assets
Assets
18150900000 usd
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
323200000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
303900000 usd
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2326000000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2126700000 usd
CY2023Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
377000000.0 usd
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
311500000 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
3026200000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2742100000 usd
CY2023Q1 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
417600000 usd
CY2022Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
430800000 usd
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
371600000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
379500000 usd
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
726500000 usd
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
685800000 usd
CY2023Q1 us-gaap Liabilities
Liabilities
4541900000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
4238200000 usd
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0 usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0 usd
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
166600000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
13100000 usd
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
257509761 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
257509761 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
257011628 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
257011628 shares
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
2600000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
2600000 usd
CY2023Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
7220200000 usd
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
7386500000 usd
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-13100000 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
800000 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
7222600000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
6522800000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
14432300000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
13912700000 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
18974200000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
18150900000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
10100000000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-4600000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
762100000 usd
CY2022Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
117500000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
36500000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
130500000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
10907000000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
13912700000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-13900000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
699800000 usd
CY2023Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
135600000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
90500000 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
165200000 usd
CY2022Q1 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
122800000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
14432300000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
699800000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
762100000 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
122400000 usd
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
130300000 usd
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
38800000 usd
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
35900000 usd
CY2023Q1 us-gaap Increase Decrease In Other Deferred Liability
IncreaseDecreaseInOtherDeferredLiability
-113400000 usd
CY2022Q1 us-gaap Increase Decrease In Other Deferred Liability
IncreaseDecreaseInOtherDeferredLiability
-12300000 usd
CY2023Q1 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
6400000 usd
CY2022Q1 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
-75600000 usd
CY2023Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-1900000 usd
CY2022Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-7500000 usd
CY2023Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-21700000 usd
CY2022Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-4900000 usd
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
82600000 usd
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-2000000.0 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-46200000 usd
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-67600000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
35700000 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-14500000 usd
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
140700000 usd
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
61600000 usd
CY2023Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
89400000 usd
CY2022Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
15700000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
899900000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
956200000 usd
CY2023Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
1816600000 usd
CY2022Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
117100000 usd
CY2023Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
50000000.0 usd
CY2022Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
129700000 usd
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
42100000 usd
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
63600000 usd
CY2023Q1 us-gaap Payments To Acquire Equity Securities Fv Ni
PaymentsToAcquireEquitySecuritiesFvNi
24900000 usd
CY2022Q1 us-gaap Payments To Acquire Equity Securities Fv Ni
PaymentsToAcquireEquitySecuritiesFvNi
0 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1833600000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-51000000.0 usd
CY2023Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
14200000 usd
CY2022Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
33700000 usd
CY2023Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
132800000 usd
CY2022Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0 usd
CY2023Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
166600000 usd
CY2022Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
117500000 usd
CY2023Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
10600000 usd
CY2022Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
12900000 usd
CY2023Q1 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
1100000 usd
CY2022Q1 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
1300000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-294700000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-95400000 usd
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12000000.0 usd
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-5900000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1216400000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
803900000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10512000000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6800100000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9295600000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7604000000 usd
CY2023Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
120300000 usd
CY2022Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
85000000.0 usd
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
11100000 usd
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
13700000 usd
CY2023Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2022Q1 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
2000000 usd
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in accordance with U.S. GAAP requires us to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of our condensed consolidated financial statements, and the amounts of revenues and expenses during the reported periods. We base our estimates on historical experience and various other assumptions, including in certain circumstances future projections that we believe to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</span></div>
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2374800000 usd
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2097500000 usd
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2374800000 usd
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2097500000 usd
CY2023Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
236400000 usd
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
159600000 usd
CY2023Q1 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
347100000 usd
CY2022Q1 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
2000000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
699800000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
762100000 usd
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
257400000 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
255100000 shares
CY2023Q1 us-gaap Incremental Common Shares Attributable To Equity Unit Purchase Agreements
IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements
0.0 shares
CY2022Q1 us-gaap Incremental Common Shares Attributable To Equity Unit Purchase Agreements
IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements
100000 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
260300000 shares
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
257900000 shares
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.72
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.99
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.69
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.96
CY2023Q1 us-gaap Cash
Cash
2100000000 usd
CY2022Q4 us-gaap Cash
Cash
3100000000 usd
CY2022Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
129000000.0 usd
CY2023Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-1900000 usd
CY2023Q1 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
127100000 usd
CY2023Q1 us-gaap Cash
Cash
2100000000 usd
CY2022Q4 us-gaap Cash
Cash
3100000000 usd
CY2023Q1 vrtx Cash Equivalents And Debt Securities Available For Sale
CashEquivalentsAndDebtSecuritiesAvailableForSale
7179300000 usd
CY2023Q1 vrtx Cash Equivalents And Debt Securities Available For Sale Gross Unrealized Gains
CashEquivalentsAndDebtSecuritiesAvailableForSaleGrossUnrealizedGains
200000 usd
CY2023Q1 vrtx Cash Equivalents And Debt Securities Available For Sale Fair Value Disclosure
CashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure
7179500000 usd
CY2022Q4 vrtx Cash Equivalents And Debt Securities Available For Sale
CashEquivalentsAndDebtSecuritiesAvailableForSale
7372900000 usd
CY2022Q4 vrtx Cash Equivalents And Debt Securities Available For Sale Fair Value Disclosure
CashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure
7372900000 usd
CY2023Q1 us-gaap Equity Securities Fv Ni Cost
EquitySecuritiesFvNiCost
129400000 usd
CY2023Q1 us-gaap Equity Securities Fv Ni Unrealized Gain
EquitySecuritiesFvNiUnrealizedGain
47400000 usd
CY2023Q1 us-gaap Equity Securities Fv Ni Unrealized Loss
EquitySecuritiesFvNiUnrealizedLoss
28700000 usd
CY2023Q1 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
148100000 usd
CY2022Q4 us-gaap Equity Securities Fv Ni Cost
EquitySecuritiesFvNiCost
104400000 usd
CY2022Q1 us-gaap Equity Securities Fv Ni Unrealized Gain
EquitySecuritiesFvNiUnrealizedGain
30900000 usd
CY2022Q1 us-gaap Equity Securities Fv Ni Unrealized Loss
EquitySecuritiesFvNiUnrealizedLoss
18500000 usd
CY2022Q4 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
116800000 usd
CY2023Q1 vrtx Debtand Equity Securities Cost
DebtandEquitySecuritiesCost
2183600000 usd
CY2023Q1 vrtx Debtand Equity Securities Unrealized Gain
DebtandEquitySecuritiesUnrealizedGain
52600000 usd
CY2023Q1 vrtx Debtand Equity Securities Unrealized Loss
DebtandEquitySecuritiesUnrealizedLoss
30500000 usd
CY2023Q1 vrtx Debtand Equity Securities Fair Value
DebtandEquitySecuritiesFairValue
2205700000 usd
CY2022Q4 vrtx Debtand Equity Securities Cost
DebtandEquitySecuritiesCost
374400000 usd
CY2022Q4 vrtx Debtand Equity Securities Unrealized Gain
DebtandEquitySecuritiesUnrealizedGain
31100000 usd
CY2022Q4 vrtx Debtand Equity Securities Unrealized Loss
DebtandEquitySecuritiesUnrealizedLoss
18800000 usd
CY2022Q4 vrtx Debtand Equity Securities Fair Value
DebtandEquitySecuritiesFairValue
386700000 usd
CY2023Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
7637100000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
5642800000 usd
CY2023Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
6555600000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
5530600000 usd
CY2023Q1 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
1081500000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
112200000 usd
CY2023Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
7637100000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
5642800000 usd
CY2023Q1 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 usd
CY2023Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
702700000 usd
CY2023Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0 usd
CY2023Q1 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
6400000 usd
CY2022Q1 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-75600000 usd
CY2023Q1 us-gaap Oci Before Reclassifications Net Of Tax Attributable To Parent
OciBeforeReclassificationsNetOfTaxAttributableToParent
3300000 usd
CY2023Q1 us-gaap Reclassification From Aoci Current Period Net Of Tax Attributable To Parent
ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
17200000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-13900000 usd
CY2022Q1 us-gaap Oci Before Reclassifications Net Of Tax Attributable To Parent
OciBeforeReclassificationsNetOfTaxAttributableToParent
11200000 usd
CY2022Q1 us-gaap Reclassification From Aoci Current Period Net Of Tax Attributable To Parent
ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
15800000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-4600000 usd
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2374800000 usd
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2097500000 usd
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1300000 usd
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-72800000 usd
CY2023Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
58100000 usd
CY2022Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
38100000 usd
CY2023Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
341100000 usd
CY2022Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
260700000 usd
CY2023Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
135900000 usd
CY2022Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
161800000 usd
CY2023Q1 us-gaap Inventory Net
InventoryNet
535100000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
460600000 usd
CY2023Q1 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
400000 usd
CY2022Q1 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
200000 usd
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
122400000 usd
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
130300000 usd
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
122400000 usd
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
130300000 usd
CY2023Q1 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
40600000 usd
CY2022Q1 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
36000000.0 usd
CY2023Q1 us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
81800000 usd
CY2022Q1 us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
94300000 usd
CY2023Q1 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
3000000000 usd
CY2023Q1 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
459017 shares
CY2023Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
135600000 usd
CY2023Q1 us-gaap Stock Repurchase Program Remaining Authorized Repurchase Amount1
StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
2900000000 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
891500000 usd
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
954800000 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
191700000 usd
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
192700000 usd
CY2023Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.215
CY2022Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.202
CY2023Q1 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
232200000 usd
CY2022Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
208500000 usd
CY2023Q1 vrtx Indemnification Claims
IndemnificationClaims
0 usd
CY2022Q4 vrtx Contingent Liabilities
ContingentLiabilities
0 usd
CY2023Q1 vrtx Contingent Liabilities
ContingentLiabilities
0 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10504000000 usd
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9289900000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6795000000 usd
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7600100000 usd
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
8000000.0 usd
CY2023Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
5700000 usd
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
5100000 usd
CY2022Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
3900000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10512000000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9295600000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6800100000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7604000000 usd

Files In Submission

Name View Source Status
0000875320-23-000012-index-headers.html Edgar Link pending
0000875320-23-000012-index.html Edgar Link pending
0000875320-23-000012.txt Edgar Link pending
0000875320-23-000012-xbrl.zip Edgar Link pending
a2023q110-qexhibit311.htm Edgar Link pending
a2023q110-qexhibit312.htm Edgar Link pending
a2023q110-qexhibit321.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vrtx-20230331.htm Edgar Link pending
vrtx-20230331.xsd Edgar Link pending
vrtx-20230331_g1.gif Edgar Link pending
vrtx-20230331_cal.xml Edgar Link unprocessable
vrtx-20230331_def.xml Edgar Link unprocessable
vrtx-20230331_lab.xml Edgar Link unprocessable
vrtx-20230331_pre.xml Edgar Link unprocessable
vrtx-20230331_htm.xml Edgar Link completed